What is HC Wainwright’s Estimate for Savara Q1 Earnings?

Savara Inc (NASDAQ:SVRA) – Analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Savara in a research report issued to clients and investors on Friday, March 28th. HC Wainwright analyst A. Fein expects that the company will earn ($0.13) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $6.00 target price on the stock. The consensus estimate for Savara’s current full-year earnings is ($0.45) per share. HC Wainwright also issued estimates for Savara’s Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.11) EPS.

Savara (NASDAQ:SVRA) last released its earnings results on Thursday, March 27th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.02). The business had revenue of $0.27 million during the quarter.

A number of other equities analysts also recently commented on SVRA. JMP Securities restated a “market outperform” rating and issued a $9.00 target price on shares of Savara in a research note on Thursday, December 19th. Wells Fargo & Company began coverage on Savara in a research note on Friday, December 20th. They issued an “overweight” rating and a $8.00 price objective on the stock. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Savara currently has a consensus rating of “Moderate Buy” and an average price target of $8.83.

Savara Trading Up 4.7 %

NASDAQ SVRA opened at $2.91 on Monday. Savara has a 12 month low of $2.26 and a 12 month high of $5.34. The company’s 50-day moving average price is $2.72 and its 200-day moving average price is $3.25. The stock has a market cap of $499.41 million, a PE ratio of -6.77 and a beta of 0.60. The company has a current ratio of 17.70, a quick ratio of 17.70 and a debt-to-equity ratio of 0.13.

Institutional Investors Weigh In On Savara

Several hedge funds have recently modified their holdings of the business. Vestal Point Capital LP raised its stake in Savara by 33.2% in the fourth quarter. Vestal Point Capital LP now owns 10,775,000 shares of the company’s stock worth $33,079,000 after buying an additional 2,685,000 shares in the last quarter. Rosalind Advisors Inc. bought a new position in shares of Savara in the 4th quarter worth $8,151,000. Nantahala Capital Management LLC lifted its stake in shares of Savara by 45.2% during the 4th quarter. Nantahala Capital Management LLC now owns 7,525,259 shares of the company’s stock worth $23,103,000 after purchasing an additional 2,344,308 shares during the last quarter. Emerald Advisers LLC bought a new stake in Savara during the fourth quarter valued at about $7,161,000. Finally, Farallon Capital Management LLC grew its stake in Savara by 49.9% in the fourth quarter. Farallon Capital Management LLC now owns 6,835,000 shares of the company’s stock valued at $20,983,000 after purchasing an additional 2,275,000 shares during the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.